CA3016491A1 - Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing gabaa receptor agonists - Google Patents

Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing gabaa receptor agonists Download PDF

Info

Publication number
CA3016491A1
CA3016491A1 CA3016491A CA3016491A CA3016491A1 CA 3016491 A1 CA3016491 A1 CA 3016491A1 CA 3016491 A CA3016491 A CA 3016491A CA 3016491 A CA3016491 A CA 3016491A CA 3016491 A1 CA3016491 A1 CA 3016491A1
Authority
CA
Canada
Prior art keywords
compound
group
compounds
iii
cognitive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3016491A
Other languages
English (en)
French (fr)
Inventor
James M. Cook
Guanguan LI
Michael Ming-Jin POE
Miroslav M. SAVIC
Etienne Sibille
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre for Addiction and Mental Health
Belgrade - Faculty Of Pharmacy, University of
UWM Research Foundation Inc
Original Assignee
Centre for Addiction and Mental Health
Belgrade - Faculty Of Pharmacy, University of
UWM Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre for Addiction and Mental Health, Belgrade - Faculty Of Pharmacy, University of, UWM Research Foundation Inc filed Critical Centre for Addiction and Mental Health
Publication of CA3016491A1 publication Critical patent/CA3016491A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CA3016491A 2016-03-18 2017-03-20 Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing gabaa receptor agonists Pending CA3016491A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662310409P 2016-03-18 2016-03-18
US62/310,409 2016-03-18
PCT/US2017/023206 WO2017161370A1 (en) 2016-03-18 2017-03-20 Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing gabaa receptor agonists

Publications (1)

Publication Number Publication Date
CA3016491A1 true CA3016491A1 (en) 2017-09-21

Family

ID=59851645

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3016491A Pending CA3016491A1 (en) 2016-03-18 2017-03-20 Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing gabaa receptor agonists

Country Status (17)

Country Link
US (4) US10906909B2 (enExample)
EP (2) EP4129297A1 (enExample)
JP (2) JP7023876B2 (enExample)
AU (2) AU2017235665B2 (enExample)
CA (1) CA3016491A1 (enExample)
CY (1) CY1125576T1 (enExample)
DK (1) DK3439665T3 (enExample)
ES (1) ES2926918T3 (enExample)
HR (1) HRP20221098T1 (enExample)
HU (1) HUE059774T2 (enExample)
LT (1) LT3439665T (enExample)
PL (1) PL3439665T3 (enExample)
PT (1) PT3439665T (enExample)
RS (1) RS63674B1 (enExample)
SI (1) SI3439665T1 (enExample)
SM (1) SMT202200372T1 (enExample)
WO (1) WO2017161370A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017313753B2 (en) 2016-08-16 2022-01-27 The Trustees Of Columbia University In The City Of New York GABA(A) receptor modulators and methods to control airway hyperresponsiveness and inflammation in asthma
US12636291B2 (en) * 2019-02-13 2026-05-26 Centre For Addiction And Mental Health Compositions and methods relating to use of agonists of ALPHA5-containing GABAA receptors
WO2020191047A1 (en) * 2019-03-18 2020-09-24 Neurocycle Therapeutics, Inc. Use of gabaa receptor modulators for treatment of pain
US12649738B2 (en) 2020-03-26 2026-06-09 Richter Gedeon Nyrt. 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine derivatives as GABAA α5 receptor modulators
TWI901650B (zh) 2020-03-26 2025-10-21 匈牙利商羅特格登公司 啶及吡啶并〔３，４－ｃ〕嗒衍生物
JP2024533306A (ja) * 2021-09-08 2024-09-12 ユーダブリューエム・リサーチ・ファウンデーション，インコーポレーテッド 認知および気分症状の処置のためのイミダゾベンゾジアゼピン
HU231691B1 (hu) 2021-09-29 2025-10-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
WO2023059443A1 (en) * 2021-10-07 2023-04-13 Pantherics Incorporated Methods and compounds for treating inflammation
US20260125388A1 (en) * 2022-10-04 2026-05-07 Uwm Research Foundation, Inc. Gaba(a) receptor modulators and methods to control smooth muscle contraction and inflammation
IT202400001089A1 (it) * 2024-01-22 2025-07-22 Fondazione St Italiano Tecnologia Composti e composizioni per l'uso nel ripristino di deficit cognitivi e comportamentali e nel miglioramento della memoria di individui nati pretermine

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA755418B (en) 1974-09-11 1977-06-29 Hoffmann La Roche Diazepine derivatives
US4226768A (en) 1979-05-29 1980-10-07 Hoffmann-La Roche Inc. Process for the preparation of imidazobenzodiazepines
US20030176456A1 (en) 2001-12-21 2003-09-18 June Harry L. Methods for reducing alcohol cravings in chronic alcoholics
USRE47475E1 (en) 2002-03-28 2019-07-02 Wisys Technology Foundation, Inc. Selective agents for pain suppression
WO2003082832A2 (en) 2002-03-28 2003-10-09 Wisys Technology Foundation, Inc. Anxiolytic agents with reduced sedative and ataxic effects
US8835424B2 (en) 2002-03-28 2014-09-16 Wisconsin Alumni Research Foundation Selective agents for pain suppression
AU2005260650A1 (en) 2004-06-30 2006-01-12 Wisys Technology Foundation, Inc. Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects
US7595395B2 (en) * 2005-05-16 2009-09-29 Wisys Technology Foundation Gabaergic agents to treat memory deficits
US20100130479A1 (en) 2005-05-16 2010-05-27 Cook James M Gabaergic Agents to Treat Memory Deficits
US7858649B2 (en) 2005-10-14 2010-12-28 Neurosearch A/S Imidazole derivatives and their use for modulating the GABAA receptor complex
DE102006023554A1 (de) 2006-05-19 2007-11-22 Zf Friedrichshafen Ag Ermittlung der Drehzahl einer Getriebewelle
US8119629B2 (en) 2007-10-03 2012-02-21 Bristol-Meyers Squibb Company Carboxamide GABAA α2 modulators
US8923318B2 (en) 2008-10-02 2014-12-30 Telefonaktiebolaget L M Ericsson (Publ) Wireless communication system and method for assigning a channel in said wireless communication system
US20100261711A1 (en) 2009-03-20 2010-10-14 Wisys Technology Foundation Selective anticonvulsant agents and their uses
US9006233B2 (en) 2011-04-28 2015-04-14 Uwm Research Foundation, Inc. Gabaergic receptor subtype selective ligands and their uses
CA2885148A1 (en) 2012-09-21 2014-03-27 Uwm Research Foundation, Inc. Novel gabaa agonists and methods of using to control airway hyperresponsiveness and inflammation in asthma
WO2016154031A1 (en) 2015-03-20 2016-09-29 Uwm Research Foundation, Inc. Gabaergic ligands and their uses

Also Published As

Publication number Publication date
AU2017235665A1 (en) 2018-09-27
HUE059774T2 (hu) 2023-01-28
US20250179080A1 (en) 2025-06-05
EP3439665A4 (en) 2019-11-27
EP3439665A1 (en) 2019-02-13
JP2019509340A (ja) 2019-04-04
DK3439665T3 (da) 2022-09-26
EP4129297A1 (en) 2023-02-08
JP7023876B2 (ja) 2022-02-22
RS63674B1 (sr) 2022-11-30
PL3439665T3 (pl) 2023-01-16
US11753412B2 (en) 2023-09-12
ES2926918T3 (es) 2022-10-31
JP2022065035A (ja) 2022-04-26
US20240083905A1 (en) 2024-03-14
WO2017161370A1 (en) 2017-09-21
AU2022275446B2 (en) 2025-01-02
SI3439665T1 (sl) 2023-05-31
EP3439665B1 (en) 2022-06-29
SMT202200372T1 (it) 2022-11-18
US20210309662A1 (en) 2021-10-07
AU2017235665B2 (en) 2022-12-08
CY1125576T1 (el) 2026-02-25
LT3439665T (lt) 2022-10-10
WO2017161370A8 (en) 2018-09-27
US12180216B2 (en) 2024-12-31
AU2022275446A1 (en) 2023-01-05
US20200181146A1 (en) 2020-06-11
JP7515526B2 (ja) 2024-07-12
PT3439665T (pt) 2022-09-27
HRP20221098T1 (hr) 2022-11-25
US10906909B2 (en) 2021-02-02

Similar Documents

Publication Publication Date Title
US12180216B2 (en) Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing GABAA receptor agonists
KR100883003B1 (ko) 알츠하이머병의 치료를 위한 글라이신 수송체1(ｇｌｙｔ-1) 억제제로서 바이- 및 트라이사이클릭 치환된페닐 메탄온
ES2942308T3 (es) Compuestos y su uso como inhibidores de BACE1
AU2017393082B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
AU2019288382B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
AU2015222805B2 (en) Treatment of conditions associated with hyperinsulinaemia
US10889584B2 (en) Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation
CA2934553A1 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
AU2021200164A1 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US10259815B2 (en) Gabaergic ligands and their uses
JP2015172098A (ja) 複素二環スピロ化合物又はその薬学的に許容される塩、これらの化合物を含む医薬組成物、および哺乳類のアルツハイマー病及びインスリン抵抗性症候群及び２型糖尿病を治療するための薬剤の調整における、これらの化合物の利用
US20240374612A1 (en) Imidazobenzodiazepines for treatment of cognitive and mood symptoms
Li Design and synthesis of achiral and chiral imidazodiazepine (IMDZ) GABA (A) R subtype selective ligands for the treatment of CNS disorders, as well as Asthma
JP7738924B2 (ja) 新規ｖｄａｃ１阻害剤
JP2020519647A (ja) グループｉｉ代謝型グルタミン酸受容体のアロステリックモジュレーターとしての置換複素環式化合物
OA19667A (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment.
ES2819309A1 (es) Compuestos agonistas nicotínicos y antioxidantes para el tratamiento de enfermedades neurodegenerativas

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220208

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250212

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250314

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250314

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250314

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250611

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250611

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250721

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250721

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260313

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260313

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260620

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260622